NASDAQ:BPMC - Blueprint Medicines Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $114.93
  • Forecasted Upside: 38.47 %
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 7 Buy Ratings
  • 1 Strong Buy Ratings
$83.00
▲ +0.22 (0.27%)

This chart shows the closing price for BPMC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Blueprint Medicines Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BPMC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BPMC

Analyst Price Target is $114.93
▲ +38.47% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Blueprint Medicines in the last 3 months. The average price target is $114.93, with a high forecast of $152.00 and a low forecast of $81.00. The average price target represents a 38.47% upside from the last price of $83.00.

This chart shows the closing price for BPMC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 14 contributing investment analysts is to buy stock in Blueprint Medicines. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 1 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/31/2019
  • 1 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/30/2020
  • 1 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/28/2020
  • 1 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/26/2020
  • 1 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 0 sell ratings
12/25/2020
  • 1 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 0 sell ratings
3/25/2021
  • 1 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
5/24/2021
  • 1 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings
6/23/2021

Latest Recommendations

  • 1 strong buy ratings
  • 7 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/17/2021WedbushLower Price TargetOutperform$136.00 ➝ $130.00High
6/17/2021SVB LeerinkBoost Price TargetOutperform$127.00 ➝ $137.00Low
6/17/2021Robert W. BairdBoost Price TargetOutperform$119.00 ➝ $123.00High
4/30/2021Morgan StanleyLower Price TargetEqual Weight$105.00 ➝ $101.00High
4/13/2021WedbushBoost Price TargetOutperform$119.00 ➝ $136.00Low
3/30/2021Credit Suisse GroupInitiated CoverageNeutral$100.00High
2/25/2021Morgan StanleyLower Price TargetEqual Weight$112.00 ➝ $105.00Low
2/18/2021HC WainwrightReiterated RatingBuyHigh
2/18/2021BarclaysBoost Price TargetEqual Weight$90.00 ➝ $95.00High
1/12/2021SVB LeerinkBoost Price TargetPositive ➝ Outperform$121.00 ➝ $127.00High
12/18/2020JMP SecuritiesBoost Price TargetOutperform$118.00 ➝ $152.00High
12/14/2020BMO Capital MarketsBoost Price TargetOutperform$113.00 ➝ $132.00Medium
12/2/2020Stifel NicolausInitiated CoverageHold$110.00High
11/2/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$90.00 ➝ $96.00High
11/2/2020HC WainwrightBoost Price TargetBuy$110.00 ➝ $135.00High
10/30/2020WedbushBoost Price Target$102.00 ➝ $115.00Low
10/30/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$112.00Low
10/29/2020Piper SandlerBoost Price TargetNeutral$77.00 ➝ $81.00Medium
10/16/2020Raymond JamesBoost Price TargetPositive ➝ Strong-Buy$106.00 ➝ $122.00Medium
10/13/2020Morgan StanleyBoost Price TargetOverweight$92.00 ➝ $100.00Low
9/23/2020SVB LeerinkBoost Price TargetOutperform$107.00 ➝ $121.00Medium
9/23/2020BMO Capital MarketsBoost Price TargetOutperform$105.00 ➝ $113.00Medium
9/23/2020BarclaysBoost Price TargetEqual Weight$77.00 ➝ $90.00Medium
9/22/2020Raymond JamesReiterated RatingBuyMedium
9/2/2020Raymond JamesReiterated RatingBuyHigh
7/31/2020HC WainwrightReiterated RatingBuyLow
7/27/2020SVB LeerinkBoost Price TargetOutperform$106.00 ➝ $107.00Medium
7/15/2020Morgan StanleyBoost Price TargetOverweight$88.00 ➝ $92.00Low
7/15/2020BarclaysReiterated RatingHold ➝ NeutralHigh
7/15/2020Deutsche Bank AktiengesellschaftBoost Price TargetBuy$85.00 ➝ $95.00Medium
7/15/2020SVB LeerinkBoost Price TargetOutperform$105.00 ➝ $106.00High
7/15/2020HC WainwrightBoost Price TargetBuy$66.00 ➝ $110.00High
7/14/2020Robert W. BairdBoost Price TargetOutperform$90.00 ➝ $100.00High
7/14/2020Raymond JamesBoost Price TargetPositive ➝ Strong-Buy$95.00 ➝ $106.00High
6/8/2020Deutsche Bank AktiengesellschaftBoost Price TargetPositive ➝ Buy$70.00 ➝ $85.00High
6/8/2020BMO Capital MarketsBoost Price TargetOutperform$75.00 ➝ $111.00High
5/7/2020HC WainwrightReiterated RatingBuy$66.00Medium
5/4/2020BarclaysInitiated CoverageEqual Weight$59.00Low
4/30/2020Canaccord GenuityLower Price TargetBuy$115.00 ➝ $100.00Low
4/30/2020Morgan StanleyLower Price TargetOverweight$103.00 ➝ $88.00Low
4/29/2020JMP SecuritiesLower Price TargetMarket Outperform$107.00 ➝ $103.00Medium
4/29/2020BMO Capital MarketsLower Price TargetOutperform$89.00 ➝ $75.00Medium
4/29/2020SVB LeerinkLower Price TargetOutperform$125.00 ➝ $105.00Medium
4/29/2020HC WainwrightLower Price TargetBuy$100.00 ➝ $66.00Medium
3/24/2020WedbushReiterated RatingOutperformHigh
3/17/2020SVB LeerinkBoost Price TargetOutperform ➝ Positive$116.00 ➝ $125.00Medium
3/17/2020BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$74.00 ➝ $89.00High
3/16/2020CowenInitiated CoverageBuyHigh
3/16/2020Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$70.00High
2/18/2020Morgan StanleyLower Price TargetOverweight$108.00 ➝ $103.00Low
2/13/2020CowenReiterated RatingBuyHigh
1/27/2020BMO Capital MarketsInitiated CoverageMarket Perform$74.00Low
1/15/2020WedbushReiterated RatingPositive ➝ Outperform$141.00 ➝ $122.00Low
1/10/2020SVB LeerinkBoost Price Target$103.00 ➝ $120.00Low
1/9/2020HC WainwrightReiterated RatingBuyMedium
12/20/2019Piper Jaffray CompaniesLower Price TargetNeutral$85.00 ➝ $77.00Low
12/10/2019Deutsche Bank AktiengesellschaftLower Price TargetHold$75.00 ➝ $70.00Low
12/2/2019Deutsche Bank AktiengesellschaftInitiated CoverageSellMedium
11/7/2019HC WainwrightReiterated RatingBuy$100.00Low
11/6/2019Raymond JamesUpgradeOutperform ➝ Strong-Buy$106.00 ➝ $112.00Medium
10/28/2019Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$110.00 ➝ $75.00High
10/22/2019JMP SecuritiesInitiated CoverageOutperform$106.00High
10/11/2019Morgan StanleyLower Price TargetOverweight$110.00 ➝ $109.00Low
10/3/2019HC WainwrightInitiated CoverageBuy$100.00High
9/30/2019CowenReiterated RatingBuyHigh
9/12/2019Raymond JamesUpgradeMarket Perform ➝ OutperformLow
9/9/2019Piper Jaffray CompaniesReiterated RatingHoldLow
9/9/2019CowenReiterated RatingBuyHigh
8/29/2019Piper Jaffray CompaniesInitiated CoverageNeutral$85.00Low
8/14/2019Raymond JamesReiterated RatingMkt Perform ➝ Market PerformHigh
8/2/2019Canaccord GenuityBoost Price TargetBuy$105.00 ➝ $120.00High
7/18/2019Robert W. BairdInitiated CoverageOutperform$120.00Medium
7/18/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$110.00Medium
6/17/2019CowenReiterated RatingBuyLow
6/2/2019CowenReiterated RatingBuyHigh
5/23/2019The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$125.00High
4/3/2019Morgan StanleyInitiated CoverageOverweight$112.00Low
3/28/2019CowenReiterated RatingBuyHigh
2/26/2019WedbushReiterated RatingOutperformHigh
2/26/2019CowenReiterated RatingBuyMedium
1/7/2019WedbushReiterated RatingOutperform$103.00High
11/15/2018CowenReiterated RatingBuyHigh
10/22/2018WedbushReiterated RatingOutperform$101.00Medium
10/8/2018WedbushReiterated RatingOutperform$101.00Low
10/7/2018CowenReiterated RatingBuyLow
9/25/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$105.00Medium
9/18/2018GuggenheimInitiated CoverageBuy$102.00High
8/1/2018CowenReiterated RatingBuyHigh
6/4/2018JMP SecuritiesLower Price TargetMarket Outperform ➝ Buy$109.00 ➝ $103.00High
4/16/2018WedbushBoost Price TargetOutperform ➝ Outperform$98.00 ➝ $106.00High
4/16/2018JMP SecuritiesSet Price TargetBuy$97.00 ➝ $109.00High
2/21/2018CowenReiterated RatingBuyLow
12/11/2017The Goldman Sachs GroupBoost Price TargetBuy ➝ Buy$82.00 ➝ $99.00High
12/11/2017JMP SecuritiesBoost Price TargetOutperform$88.00 ➝ $97.00High
12/10/2017Raymond JamesSet Price TargetBuy$82.00High
11/10/2017CowenReiterated RatingBuyN/A
11/6/2017WedbushReiterated RatingOutperform$70.00 ➝ $82.00N/A
11/1/2017Canaccord GenuityReiterated RatingBuy$66.00 ➝ $80.00N/A
10/31/2017CowenReiterated RatingBuyN/A
10/23/2017Morgan StanleyBoost Price TargetOverweight$45.00 ➝ $78.00N/A
9/29/2017DA DavidsonInitiated CoverageBuy$90.00High
9/29/2017BTIG ResearchInitiated CoverageBuy ➝ Buy$90.00High
9/20/2017The Goldman Sachs GroupReiterated RatingBuy$64.00 ➝ $79.00Low
9/20/2017Canaccord GenuityBoost Price TargetBuy$56.00 ➝ $66.00Medium
9/11/2017Canaccord GenuityReiterated RatingBuy$56.00Low
9/5/2017Jefferies Financial GroupReiterated RatingBuy$56.00Medium
8/22/2017WedbushReiterated RatingOutperform$66.00High
8/2/2017Canaccord GenuitySet Price TargetBuy$52.00 ➝ $56.00Medium
6/6/2017Canaccord GenuitySet Price TargetBuy$52.00Low
6/6/2017CowenReiterated RatingBuyLow
6/6/2017WedbushReiterated RatingOutperform$55.00Low
5/4/2017Jefferies Financial GroupBoost Price TargetBuy$42.00 ➝ $52.00Medium
4/5/2017WedbushBoost Price TargetOutperform ➝ Outperform$43.00 ➝ $50.00Low
4/4/2017Canaccord GenuityBoost Price TargetBuy$40.00 ➝ $42.00Low
3/22/2017JMP SecuritiesInitiated CoverageOutperform$37.00 ➝ $46.00Low
3/13/2017The Goldman Sachs GroupUpgradeNeutral ➝ Buy$52.00High
2/15/2017Morgan StanleyInitiated CoverageOverweight$45.00N/A
12/14/2016Jefferies Financial GroupInitiated CoverageBuy$40.00N/A
12/6/2016WedbushReiterated RatingOutperform$43.00N/A
12/5/2016CowenReiterated RatingBuy$38.33 ➝ $33.19N/A
12/1/2016JMP SecuritiesReiterated RatingBuyN/A
11/29/2016WedbushReiterated RatingOutperform$43.00 ➝ $41.00N/A
11/12/2016Canaccord GenuitySet Price TargetBuy$35.00N/A
11/10/2016WedbushReiterated RatingOutperform$41.00N/A
11/3/2016CowenReiterated RatingBuyN/A
8/9/2016CowenReiterated RatingBuyN/A
8/9/2016WedbushReiterated RatingOutperform$41.00N/A
8/5/2016Canaccord GenuityInitiated Coverage` ➝ Buy$26.00N/A
(Data available from 6/23/2016 forward)
Blueprint Medicines logo
Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase 1b/2 trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib for the treatment of RET-altered non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945, a selective and potent investigational inhibitors of double-mutant EGFR harboring, which are in preclinical stage for patient with EGFR-driven NSCLC. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $83.00
Low: $81.70
High: $83.78

50 Day Range

MA: $91.63
Low: $82.78
High: $101.00

52 Week Range

Now: $83.00
Low: $66.20
High: $125.61

Volume

1,180,640 shs

Average Volume

469,887 shs

Market Capitalization

$4.84 billion

P/E Ratio

14.74

Dividend Yield

N/A

Beta

0.69

Frequently Asked Questions

What sell-side analysts currently cover shares of Blueprint Medicines?

The following Wall Street analysts have issued stock ratings on Blueprint Medicines in the last year: Barclays PLC, BMO Capital Markets, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, Morgan Stanley, Piper Sandler, Raymond James, Robert W. Baird, Stifel Nicolaus, SVB Leerink LLC, TheStreet, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for BPMC.

What is the current price target for Blueprint Medicines?

14 Wall Street analysts have set twelve-month price targets for Blueprint Medicines in the last year. Their average twelve-month price target is $114.93, suggesting a possible upside of 38.5%. JMP Securities has the highest price target set, predicting BPMC will reach $152.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $81.00 for Blueprint Medicines in the next year.
View the latest price targets for BPMC.

What is the current consensus analyst rating for Blueprint Medicines?

Blueprint Medicines currently has 6 hold ratings, 7 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BPMC will outperform the market and that investors should add to their positions of Blueprint Medicines.
View the latest ratings for BPMC.

What other companies compete with Blueprint Medicines?

How do I contact Blueprint Medicines' investor relations team?

Blueprint Medicines' physical mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company's listed phone number is 617-374-7580 and its investor relations email address is [email protected] The official website for Blueprint Medicines is www.blueprintmedicines.com.